Table 2 Model inputs: costs
From: Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
| Event cost ($) | |||
|---|---|---|---|
| Base-case | Lower bound | Upper bound | |
| Treatment Costs | |||
| Cost of annual treatment | |||
| Asenapine | 1,030.00 | N/A | N/A |
| Olanzapine [41] | 1,871.00 | 1,316.00 | 2,426.00 |
| -Cost of EPS management [42] | 60.00 | 0.00 | N/A |
| Costs associated with long-term metabolic complications | |||
| Direct costs* | |||
| Diabetes | 3,834.77 | 1,215.00 | 17,072.00 |
| Hypertension | 571.00 | 233.00 | 827.00 |
| CHDs | |||
| Fatal CHDs | 7,093.20 | 775.00 | 52,617.00 |
| CHDs (Year 1) | 2,481.24 | 818.00 | 8,819.00 |
| CHDs (Year 2–5) | 1,146.11 | 360.00 | 5,795.00 |
| Stroke | |||
| Fatal stroke | 30,776.93 | 7,362.00 | 34,165.00 |
| Stroke (Year 1) | 4,034.86 | 1,395.00 | 10,560.00 |
| Stroke (Year 2–5) | 1,867.59 | 452.00 | 8,692.00 |
| Productivity losses[28, 43]–[46] | |||
| Diabetes | 528.00 | 396.00 | 660.00 |
| Hypertension | 119.00 | 89.25 | 148.75 |
| CHDs | 3,109.00 | 2,331.75 | 3,886.25 |
| Stroke | 4,322.00 | 3,241.50 | 5,402.50 |
| Informal care[47] | |||
| Stroke | 3,770.00 | 2,827.50 | 4,712.50 |
